The FDA has approved TargetScan, a new device for conducting prostate biopsies.
The FDA has approved TargetScan, a new device for conducting prostate biopsies. The device combines 3-D image acquisition with a stationary probe to help physicians plan and execute targeted prostate biopsies, potentially improving patients' cancer treatment outcomes with less-invasive procedures, according to its manufacturer, Envisioneering Medical Technologies, St. Louis.
"We've learned that current diagnostic tools are inadequate-missing cancer in some patients while over testing others," said Gerald Andriole, MD, of Washington University School of Medicine, St. Louis, and a member of the Envisioneering medical advisory board. "With TargetScan, we anticipate improved cancer detection-saving time, money and possibly lives."
The device also plays a role in prostate cancer treatment. It eliminates the need to physically move the probe, so the prostate position will be stabilized during radioactive seed implantation.
TargetScan is currently available in select U.S. urology clinics for field testing. A widespread launch is planned in conjunction with the AUA annual meeting in May.